By Clara MacKay, CEO, World Ovarian Cancer Coalition
24 March 2025
The Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer is an important touchpoint for the entire community – clinicians, researchers, and those of us in advocacy. A key opportunity to learn about the latest advancements in gynecologic cancer treatment and research.
With no effective screening tool, ovarian cancer prevention remains a crucial area of exploration. The latest update at SGO 2025 on the TUBA-WISP II study was a particularly welcome addition to the program. This study, focused on women at high risk of inherited ovarian cancer, prioritizes preserving quality of life without compromising the benefits of risk-reducing surgery – an essential consideration for those facing these decisions.
The program also included an update on study data highlighting the benefits
of antibody-drug conjugates (ADCs) in treating platinum-resistant ovarian
cancer. ADCs are the new players in ovarian cancer treatment – this is an
encouraging development with significant potential.
Most importantly, it was a privilege and a joy to witness ovarian cancer advocates take the stage, sharing their experiences, insights, and priorities. The advocacy panel at the Patient & Advocate Education Forum was the most powerful I’ve ever attended. Speakers addressed everything from the stigma of a gynecologic cancer diagnosis to its impact on relationships, mental health, and faith – and the hope they carry for those who will follow in their footsteps. We are in good hands with such powerful advocates on our side.